Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of pridopidine in Huntington's disease
2026-526093-16-00Phase 3Authorised
- Sponsor
- Ferrer
- Start
- Oct 2026
- Modality
- Small Molecules
- Countries
- 12
01
Overview
Phase 3, randomised, double-blind trial in Huntington disease (HD) comparing Pridopidine with Placebo (2 arms). Primary endpoint: Change from baseline to Week 52 in cUHDRS. Planned start Oct 2026; status: authorised.
02
Drugs
pridopidine
03
Conditions
Huntington disease (HD)
Beyond the preview
Go deeper on 2026-526093-16-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-526093-16-00.